In Phase C, members will obtain ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until illness progression or even the individuals are unable to tolerate the study drugs. There might be higher treatment burden for participants On this trial when https://abbv-744cancertreatmentcl13562.kylieblog.com/32445243/abbv-744-in-combination-with-immunotherapy-an-overview